MDL | - |
---|---|
Molecular Weight | 432.33 |
Molecular Formula | C23H14Na2O6 |
SMILES | OC1=C(C(C=CC=C2)=C2C=C1C(O[Na])=O)CC(C(C=CC=C3)=C3C=C4C(O[Na])=O)=C4O |
Pamoic acid disodium is a potent GPR35 agonist with an EC 50 value of 79 nM. Pamoic acid disodium induces GPR35 internalization and activates ERK1/2 with EC 50 values of 22 nM and 65 nM, respectively. Pamoic acid disodium potently recruits β-arrestin2 to GPR35 and has an antinociceptive effect [1] .
EC50: 79 nM (GPR35), 65 nM (ERK1/2) [1]
Pamoic acid (0.1 nM-0.1 mM) induces GPR35a internalization with an EC
50
value of 22 nM
[1]
.
Pamoic acid (0-10 μM) induces ERK1/2 activation
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
Cell Line: | U2OS cells |
Concentration: | 1, 10, 100 nM and 1, 10 μM |
Incubation Time: | 15 min |
Result: | A concentration-dependent activation of ERK1/2 was observed with an EC 50 of 65 nM. |
Pamoic acid disodium (0-100 mg/kg; s.c.; once) induces a dose-related antinociception in the abdominal constriction test [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Swiss-Webster mice (30–35 g) [1] |
Dosage: | 25, 50, and 100 mg/kg |
Administration: | Subcutaneous injection, once |
Result: | Elicited dose-related antinociception, the dose causing 50% antinociception being 40.5 mg/kg. |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : 100 mg/mL ( 231.30 mM ; ultrasonic and warming and heat to 60°C)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.3130 mL | 11.5652 mL | 23.1305 mL |
5 mM | 0.4626 mL | 2.3130 mL | 4.6261 mL |
10 mM | 0.2313 mL | 1.1565 mL | 2.3130 mL |
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 7.5 mg/mL (17.35 mM); Clear solution